Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares Alkermes
So what: Strong demand for RISPERDAL CONSTA, a treatment for schizophrenia and bipolar disorder, drove results. Revenue came in at $43.9 million, about even with last year's Q3. Net loss per share came in at $0.12. Analysts were expecting a $0.15 per share loss on $43.2 million in revenue.
Now what: Biotech is a tough business, but Alkermes seems to be doing well at it. At the same time it reported results, the company also said that its partner in developing the diabetes treatment BYDUREON, Amylin Pharmaceuticals
Fool contributor Tim Beyers is a member of the Motley Fool Rule Breakers stock-picking team. He didn't own shares in any of the companies mentioned in this article at the time of publication. Check out Tim's portfolio holdings and Foolish writings, or connect with him on Twitter as @milehighfool. You can also get his insights delivered directly to your RSS reader.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool is also on Twitter as @TheMotleyFool. Its disclosure policy is at least 10% better than other disclosure policies.